Has there been no new option for first-line treatment of stomach cancer for more than a decade?

Since the FDA approved HER2 antibody Herceptin for HER2-positive metastatic gastric cancer in 2010, the FDA has not approved any new first-line treatments for metastatic stomach cancer.
for HER2-negative patients, who account for 80 percent of total stomach cancer patients, the current first-line therapy is still the same systemic chemotherapy combination as it was in the 1990s.
, however, with advances in targeted therapies and immunotherapy, multiple combination therapies have yielded positive results in clinical trials for stomach cancer.
today, the Drug Mingkang content team will present the latest results of several gastric cancer treatments reported at the American Society of Clinical Oncology-Gastrointestinal Cancer Symposium (ASCO-GI), which concluded last week.
it is worth mentioning that a number of Chinese pharmaceutical companies have been involved in the clinical development of these innovative therapies and have obtained their development interests in China.
with the introduction of more than $400 million in Baiji Shenzhou, HER2 targets the early clinical results of dual-specific antibody therapy positively developed by Zymeworks with a dual-specific antibody zandatamab that binds to both non-overlapping tables of HER2.
This unique design creates a variety of mechanisms of action, including double blocking of HER2 signals, enhancing the removal of HER2 proteins from cell surfaces, and increasing antibody-mediated cytotoxicity to produce encouraging anti-tumor activity in patients.
has been identified by the FDA as a breakthrough therapy for her2-positive bile cancer.
and obtained FDA-granted fast-track eligibility, in combination with chemotherapy, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA).
on ASCO-GI, Zymeworks published clinical results for phase 1 of the treatment of GEA patients with zanidatamab monodrimab or in combination with chemotherapy.
trial results showed that zanidatamab monotherapy had a partial remission rate (PR) of 39 percent and a disease control rate (DCR) of 39 percent in patients who had previously been treated with Herceptin.
combination of Zanidatamab and chemotherapy was more effective, achieving a 54% confirmed objective remission rate, including a fully remission patient.
79 per cent.
the medium duration was 8.9 months and the medium non-progression lifetime was 5.6 months.
, in November 2018, the state acquired exclusive development and commercial rights for zandatamab and another drug in development in Asia (excluding Japan), Australia and New Zealand with a down payment of $40 million and a potential milestone payment of $390 million.
, zanidatamab has been approved to conduct clinical trials in China to treat HER2-positive bile disease patients with a single drug.
Zymeworks said it would launch a key clinical trial in the middle of this year to test the efficacy of zanidatamab in combination with chemotherapy, as well as the PD-1 inhibitor developed by Baiji Shenzhou in combination with Tislelizumab, a first-line treatment for HER2-positive GEA patients.
first-line treatment for stomach cancer, the combination of FGFR2b inhibitors reduces the risk of death by 42% Five Prime Therapeutics developed bemarituzumab as a potential "first-in-class" FGFR2b monoclonal antibody.
it has a dual mechanism of action, not only by binding with FGFR2b, blocking the signaling of its mediated growth factors, but also by antibody-dependent cell-mediated cytotoxic action (ADCC) to kill cancer cells.
Hastings Pharmaceuticals has entered into a partnership agreement withIve Prime to develop this innovative therapy in Greater China and is responsible for its clinical trials in Greater China.
Phase 2 clinical trial results published in ASCO-GI showed that bemarituzumab and chemotherapy were associated with chemotherapy to reduce the risk of death by 42% in FGFR2b-positive patients (HR=0.58, 95% CI, 0.35-0.95, p=0.0268).
survival of the patient group treated with combination therapy had not yet been reached, and the control group was 12.9 months.
and analysis of the trial data showed that the higher the level of overexploitation of FGFR2b in the patient's tumor, the more likely they were to benefit from this combination therapy.
Said Prime said it would conduct a global Phase 3 clinical trial to further test the efficacy of this combination of first-line treatments for FGFR2b-positive gastric cancer patients.
30% of patients with stomach cancer who did not express HER2 may overexploit FGFR2b.
first-line therapy HER2-negative GEA, Keytruda/chemotherapy combination showing anti-cancer activity The PD-1 inhibitor Keytruda (pembrolizuamb) developed by MSD has been approved by the FDA as a 2-line therapy for patients with PD-L1-positive advanced stomach cancer.
at ASCO-GI, researchers at Duke University School of Medicine reported the results of a Phase 2 clinical trial using Keytruda in combination with chemotherapy to treat patients with HER2-negative stomach cancer.
In this one-arm Phase 2 clinical trial, Keytruda was associated with the chemotherapy drugs capecitabine and oxaliplatin to achieve a 72.7 percent mitigation rate, with a medium progression-free lifetime of 7.6 months and a medium total survival of 15.8 months.
5 out of 34 patients who were able to assess efficacy remained in continuous and complete remission after more than 18 months of follow-up.
, Mercadon has launched a randomized double-blind, global Phase 3 clinical trial, KEYNOTE-859, to test the efficacy of Keytruda in combination with chemotherapy, a first-line treatment for HER2-negative patients with advanced stomach cancer.
patient recruitment is ongoing.
study, published in ASCO-GI, also showed that Keytruda and Herceptin, as well as chemotherapy-made 3-in-3 therapy, also showed good results in first-line treatment of HER2-positive stomach cancer.
we wish these innovative therapies a clinical success and bring new first-line treatment options to patients with stomach cancer at an early time.
: This article is intended to introduce medical and health research, not treatment options recommended.
if you need guidance on treatment options, visit a regular hospital.
: s1. Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Processing as Frontline Targeted for FGFR2b plus Treatment Gastric and GEJ Cancers. Retrieved January 17, 2021, from [2] Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium. Retrieved January 17, 2021, from [3] Zanidatamab ASCO GI Webcast. Retrieved January 17, 2021, from [4] Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium. Retrieved January 17, 2021, from [5] KEYlargo: A phase II study of first-line pembrolizumab (P), capecitabine (C), and oxaliplatin (O) in HER2-negative gastroesophageal (GE) adenocarcinoma. Retrieved January 17, 2021, from